Company Overview of Fab'entech- Immeuble Domilyon
Fab'entech- Immeuble Domilyon, a biopharmaceutical company, develops and commercializes passive immunotherapeutic solutions based on specific polyclonal immunoglobulins for emerging infectious diseases and various drug intoxications. The company offers Fabenflu, a passive immunotherapy product for use in the case of post-exposure to H5N1 avian influenza virus. Its products pipeline also includes Anti-CCHF product, which targets Crimean-Congo hemorrhagic fever virus; Anti-Nipah/Hendra product that targets Hendra and Nipah viruses; and other products, which target emerging infectious diseases and drug intoxication. The company was founded in 2009 and is based in Lyon, France.
24 rue Jean Baldassini
Founded in 2009
33 4 37 70 67 67
33 4 37 70 67 68
Key Executives for Fab'entech- Immeuble Domilyon
Fab'entech- Immeuble Domilyon does not have any Key Executives recorded.
Similar Private Companies By Industry
|Acticor Biotech SAS||Europe|
|Aelis Farma S.A.S.||Europe|
|Aenitis Technologies SAS||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Fabentech- Immeuble Domilyon, please visit www.fabentech.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.